Equity Overview
Price & Market Data
Price: $19.66
Daily Change: +$0.23 / 1.17%
Daily Range: $19.16 - $19.94
Market Cap: $996,220,032
Daily Volume: 532,675
Performance Metrics
1 Week: 1.34%
1 Month: -3.49%
3 Months: 6.33%
6 Months: 46.83%
1 Year: 103.5%
YTD: 5.08%
Company Details
Employees: 97
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.